Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Investig Med High Impact Case Rep ; 11: 23247096231165728, 2023.
Article in English | MEDLINE | ID: mdl-37073469

ABSTRACT

Combined central retinal artery and vein occlusion (CCRAVO) is a rare entity characterized by features of tortuous retinal veins, retinal hemorrhage, optic disk edema and pallor, macula edema, cherry-red spot, and cotton-wool spots. The occurrence of CCRAVO in the adult population is often in the setting of systemic disease; while CCRAVO in the pediatric population is frequently associated with infection of the sinuses, preseptal cellulitis, or orbital cellulitis. It has been hypothesized that CCRAVO can result from methicillin-resistant Staphylococcus aureus (MRSA) sepsis-induced coagulation disturbances, orbital cellulitis, and even orbital compartment syndrome; however, there are insufficient reports of this complication. This case report sheds light on one such case with irreversible vision loss as a sequela.


Subject(s)
Methicillin-Resistant Staphylococcus aureus , Orbital Cellulitis , Retinal Artery , Sepsis , Adult , Humans , Child , Orbital Cellulitis/complications , Orbital Cellulitis/drug therapy , Anti-Bacterial Agents/therapeutic use , Sepsis/complications
2.
J Investig Med High Impact Case Rep ; 11: 23247096221150636, 2023.
Article in English | MEDLINE | ID: mdl-36661254

ABSTRACT

Immune-mediated necrotizing myopathy (IMNM) is a subtype of inflammatory myopathy that is characterized by proximal muscle weakness, markedly elevated serum creatine kinase, myopathic electromyographic findings, and muscle biopsies revealing necrosis or regeneration with sparse inflammatory infiltrate. IMNM tends to be idiopathic but has been associated with certain medications. This supports the possibility for other pharmacotherapies to induce IMNM-particularly leflunomide. Leflunomide is used in the treatment for rheumatoid arthritis and has been shown to induce autoimmune diseases-including autoimmune hepatitis and polymyositis. After an extensive review of history and workup of muscle weakness, we conclude that leflunomide induced an IMNM in our patient. As this is the first case of leflunomide-induced IMNM, it is important for clinicians to suspect an inflammatory myopathy in the setting of myositis while on leflunomide.


Subject(s)
Arthritis, Rheumatoid , Autoimmune Diseases , Myositis , Humans , Leflunomide/adverse effects , Muscle, Skeletal/pathology , Myositis/chemically induced , Myositis/complications , Autoimmune Diseases/chemically induced , Autoimmune Diseases/complications , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/pathology , Muscle Weakness
SELECTION OF CITATIONS
SEARCH DETAIL
...